Atezolizumab 1.2g/20ml solution for infusion vials
NHS hospitals in England used £37,887,778 of indicative cost of Atezolizumab 1.2g/20ml solution for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is down 29.9% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Atezolizumab 1.2g/20ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Atezolizumab 1.2g/20ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| King's College Hpl Nhs Foundation Trust | £2,537,064 |
| United Lincolnshire Hospitals Nhs Trust | £2,471,191 |
| The Royal Marsden Nhs Foundation Trust | £1,858,914 |
| The Christie Nhs Foundation Trust | £1,688,330 |
| Sheffield Teaching Hospitals Nhs Trust | £1,400,468 |
| The Clatterbridge Cancer Centre Nhs Ft | £1,304,515 |
| Northampton General Hosp Trust | £1,096,615 |
| Imperial College Healthcare Nhs Trust | £1,046,353 |
| Worcestershire Acute Hpls Nhs Trust | £1,027,315 |
| Guy's & St Thomas' Nhs Foundation Trust | £989,999 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.